Aims: To evaluate the feasibility and acceptability of an addiction program within the setting of liver transplantation, with classification of behavior change techniques used to reduce excessive drinking. Method: Patients with alcohol-related liver disease (N = 100) participated in a manualized addiction group therapy over 12 sessions, pre-transplantation. Relapses were identified by measurement of urinary ethyl glucuronide (EtG). Results: Two groups were identified according to the frequency of participation: completers (n = 42) vs. drop-outs (n = 58). A total of 16.5% of the samples of completers in comparison to 30.5% of the samples of drop-outs tested positive for EtG (P < 0.001).
INTRODUCTION
Approximately 25-35% of all liver transplantations conducted in the Western world are in patients in the final stage of alcohol-related liver disease (ALD) and the overall clinical outcome compares favorably after transplant for other liver diseases (Burra et al., 2010; Carbone and Neuberger, 2010; Lucey, 2011) . It is generally accepted that ALD patients should refrain from alcohol consumption before transplantation, as abstinence can reduce the risk for severe complications (McCormick et al., 1992) . Furthermore, recidivism after transplantation may lead to a reduced long-term survival rate (Schmeding et al., 2011; Faure et al., 2012) . Survival rates of patients who continue abusive drinking are significantly lower than those of abstinent patients or patients with minor lapses (Pfitzmann et al., 2007) . The predictive viability of a 6-month abstinence interval for recidivism is controversial but still widely applied in transplant settings (Kelly et al., 2006; Kawaguchi et al., 2013; Dom et al., 2015) . Dom et al. (2015) described in a review of alcohol relapse assessments and treatments for ALD patients before liver transplantation that in addition to an abstinence interval the individual risk for relapse should regularly be examined by a specialist to prevent alcohol relapse pre-and post-transplantation. Reported relapse rates after surgery have mostly been based on retrospective data collection without using objective measures of alcohol consumption (De Gottardi et al., 2007) . Recently, in studies based on self-or family reports, relapse rates of 15-25% were reported among ALD patients on a liver transplant waiting list (Iasi et al., 2003; DiMartini et al., 2010; Webzell et al., 2011) . Measuring methanol levels in urine, Hempel et al. (2012) showed that one-third of the urine samples, collected at different time points during the evaluation process before listing, tested positive. Based on these observations, activities to promote alcohol abstinence in ALD patients are highly recommended before transplantation. Up to date, there is little evidence for the effectiveness of pharmacological treatments for patients with end-stage ALD awaiting liver transplantation. Especially, severe dysfunction of the liver has to be considered in the selection of the adequate medication for endstage ALD patients (Dom et al., 2015) . To date, only baclofen has been investigated in patients with alcoholic liver disease, results indicating benefits in craving and abstinence (Addolorato et al., 2007) . Relapse prevention should be a multidisciplinary concern both before and after transplantation, and should be initiated as early as possible. Recently, toxicology screening, at least in the initial evaluation before transplantation, has been proposed (DiMartini and Dew, 2012) and the jury of the Consensus Conference in 2006 recommended addiction therapy to be routinely implemented and its efficacy evaluated. However, only a small amount of information on addiction programs within the setting of liver transplantation is currently available (Consensus Conference: Indications for liver transplantation, January 19 and 20, 2005, Lyon-Palais Des Congres, 2006) . The beneficial effects of an addiction unit in an Italian liver transplant center were recently reported (Addolorato et al., 2013) . After transplantation, the patients supported by the addiction unit demonstrated a lower prevalence of alcohol relapse and also a lower mortality rate, compared with the patients not receiving such supportive therapy.
Pilot studies attempting to modify drinking behavior suggested that giving supportive treatment after transplantation was not successful, whereas starting treatment prior to transplantation may be effective (Weinrieb et al., 2001; Georgiou et al., 2003) . To our knowledge, few study groups have reported on psychosocial interventions for patients with ALD. Georgiou et al. (2003) described an intervention consisting of three sessions integrated into the transplantation process, which were conducted in the pre-transplantation period. The main objective was to develop sufficient social support for change and modification of the drinking behavior. The intervention was accepted by the patients and practicable for the staff, but concrete outcome measures have not yet been presented. A randomized controlled study comparing the effects of a motivational addiction therapy with treatment as usual (Weinrieb et al., 2001) , found no significant difference with regard to psychosocial health or general health outcomes. However, that therapy seemed to reduce the quantity and frequency of pre-transplant alcohol consumption.
The objective of this study was to evaluate the feasibility, acceptability and effects of an addiction therapy in 100 ALD patients, before liver transplantation. We recorded relapses by measuring urinary ethyl glucuronide (EtG) during the 6-month therapy program. For additional analyses, the total sample was divided into two groups according to therapy participation (completer vs. drop-outs). The aim was to examine group differences regarding relapses (EtG values).
METHODS

Design and subjects
The study followed a prospective naturalistic design. Participants were enrolled in group therapy over 6 months with 12 biweekly sessions. The number of relapses during the therapy was held as primary outcome measure. We included liver transplant candidates with ALD in the terminal stage at the University Hospital of Essen according to the following recruitment procedure and criteria: Patients with ALD listed or in preparation for transplantation underwent a psychosomatic screening interview conducted by a specialized physician or psychologist. In addition, the Transplant Evaluation Rating Scale (TERS) was used. Criteria for alcohol use disorders according to ICD-10 were checked in the psychosomatic screening interview and the diagnosis of alcoholic liver disease confirmed in the medical history. Alcohol abstinence status and risk of alcohol intake or recidivism were explored to evaluate their suitability as transplant recipient. In detail, length of self-reported alcohol abstinence preceding the visit (more or less than 6 months) and risk factors for alcohol relapse were examined such as lack of insight and lack of motivations regarding alcohol misuse, lack of participation in previous therapy programs or Anonymous Alcoholics groups, lack of coping skills and social support and an alcohol use disorder of first degree biological relatives or cohabitating spouses. Furthermore, patients were asked to specify their current and past (6 months prior to the visit) drinking behavior. Patients evaluated to be at high risk for alcohol relapse were asked to participate in the study, whereas patients with ongoing heavy alcohol use were referred to inpatient treatment. Only patients with an alcohol-related primary cause of liver disease were included. In addition, psychiatric comorbidities were assessed using the patient's medical history report written by their general practitioner or medical specialist.
During the recruitment period a total of 437 patients were examined for liver transplantation at the University Hospital of Essen. Half of the patients (n = 219) suffered from non-alcoholic liver disease and were therefore excluded from the study. The remaining 218 patients with an alcoholic liver disease were consecutively assigned to two groups: low/moderate risk vs. high risk for alcohol-related problems. Group assignment was based on the specialized physician's/psychologist's experience and the use of the TERS (Twillman et al., 1993) . TERS is a standardized psychological assessment to evaluate psychosocial functioning of transplant candidates. It consists of ten parameters ( prior psychiatric history with axis one and two disorders, compliance, health behaviors, quality of family and social supports, mental status, prior and current history of coping, quality of affect, substance abuse) and can be summed up into a TERS total score ranging between 26.5 and 79.5. Higher TERS total scores indicate a higher impairment of psychosocial adjustment.
Individuals assigned to the low/moderate risk group were excluded from the study, whereas individuals with high risk for alcohol-related problems were included. Thus, a consecutive group of 100 participants were included in the study. All patients participated voluntarily in the study and provided written informed consent. The study was approved by the Ethics Committee of the University Hospital of Essen. After finishing the allocated group therapy, patients were divided into two groups according to the frequency of participation. As the cut off we chose a participation of three quarters of the total sessions, which was also supported by the median. Accordingly, patients who attended more than nine sessions were defined as 'completer', whereas those who attended up to nine sessions were defined as 'drop-out'. See Fig. 1 (Flow-Chart).
Treatment procedure and contents
Group therapy was conducted by the first author (YE) together with changing co-therapists. It consisted of twelve biweekly sessions over 6 months and took place in the University Hospital of Essen, Germany. With exception of the first session, urinary samples were collected from the participants at every session.
Therapy duration was adjusted to the 6 months sobriety rule. German health insurances pay for alcohol withdrawal and rehabilitation therapies but it takes several months to find admission and start therapy. The therapy group established in the transplant center secured initiation of therapy without waiting time.
The therapy is based on cognitive-behavioral models of addiction and includes the elements of psycho-education, situational analysis, abstinence contracting, progressive muscle relaxation and problemsolving training. The aim of the therapy is to reduce slips and relapses and stabilize physical health. A standardized manual has been compiled and its practicability and impact evaluated (Erim et al., 2006a, b) . The therapy manual was developed according to our clinical observation that ALD patients could not integrate very well into self-help groups such as Alcoholics Anonymous (AA). The situation of imminent transplantation causes further preoccupations that are not addressed in AA groups. ALD patients often felt distressed and developed feelings of guilt in group conversations focusing mainly on past alcohol consumption. Therefore, we established our therapy attitude, which follows principles of motivational interviewing (Miller et al., 1991) . The first module of the therapy focuses on psycho-education. Information on liver transplantation is summarized in a film. In a further session patients can discuss their questions with the transplant hepatologist (SB and ChK). These informative sessions are open for both caregivers and patients' families. Information is also supplied on alcohol addiction in combination with individual analyses of relapse-risk situations. In the second module, problem-solving training (D'Zurilla and Goldfried, 1971 ) is conducted. Patients work on situations out of their daily life with an emphasis on addiction-related problems. We analyzed previous alcohol consumption and provided information to facilitate refraining from alcohol. Additionally, feedback including disclosure of the EtG results during the sessions was a crucial tool. For a clear specification and description of the applied therapy, a summary of the interventions according to the novel classification published by Michie (Michie et al., 2012 (Michie et al., , 2013 ) is displayed in Table 1 .
Outcome measurements
For early detection of relapses, we measured urinary EtG, a conjugated ethanol metabolite with a longer detection window than urinary ethanol (Helander et al., 2009 ) and demonstrated to be superior to patient's self-report and breath testing, in this setting (Erim et al., 2007; Schieber et al., 2015) . EtG captures drinking behavior up to a few days before testing. Therefore its assessment window is suitable to detect relapses in patients who drink regularly (Allen et al., 2013) . EtG detection time depends on the amount of ethanol intake. Prior studies have shown that EtG 'made it possible to detect a single alcohol intake several hours up to some days afterwards, the time window largely being dose-dependent' (Helander et al., 2012) . Specifically, EtG can be detected in the urine >6 h after intake of a low ethanol dose (7 g), >20 h after intake of 25-40 g and typically >50 h after drinking at least 100 g ethanol (Stephanson et al., 2002; Borucki et al., 2005) . A measurement with a longer detection time would not have been adequate for this study as the primary objective was to detect recent relapses. In addition, the measurement also served as a therapeutic feedback device. Before starting the sessions, urine samples for measurement of EtG were collected under observation by a study nurse. The specimens were stored at −70°C until shipped in dry ice for measurement of EtG, by liquid chromatography-mass spectrometry (Helander et al., 2010) . The screening cutoff was 0.10 mg/L and the lower limit of quantification of the LC-MS/MS method was 0.05 mg/L for EtG. To exclude intentional dilution of the urine samples by drinking large amounts of water prior to voiding, urinary creatinine was determined by the routine Jaffe reaction (ThermoFisher Scientific) on an Olympus AU680. Positive EtG results (>0.05 mg/L with LC-MS/MS) were defined as relapses and were communicated to the patients in the next therapy session.
Statistical analyses
Patient characteristics and socio-demographic data are presented as means (SD) for continuous variables and numbers (%) for categorical variables. Between-group differences were assessed using nonparametric Wilcoxon rank sum tests for continuous variables and Fisher's exact-test for categorical variables. Differences between repeated measurements (e.g. scores from baseline and end of treatment) were assessed via Wilcoxon's signed rank test. Statistical analyses were performed using IBM SPSS Statistics for Windows Version 22.0 (SPSS Armonk, NY: IBM Corp.) and the statistical programing environment R 3.0.2 (R Foundation for Statistical Computing, http://www. R-project.org/).
RESULTS
Socio-demographic data and clinical parameters
Our sample consisted of 100 patients with a mean age of 52.8 years (SD = 7.9); 61% were males, 66% were married. All patients were diagnosed with end-stage ALD. In a routine interview according to the criteria of ICD-10 alcohol dependence was diagnosed in 64% of the patients and alcohol abuse in 36% of the patients. At the time of the screening interview 47% reported a 6-month abstinence, whereas 53% reported to have consumed alcohol during the 6 months before the psychosomatic interview. Comorbid somatic diagnoses were hepatitis C (n = 17) and hepatitis B virus infection (n = 2), autoimmune hepatitis (n = 1) and hepatocellular carcinoma (n = 1). Concomitant psychiatric diagnoses were previous or current depressive episodes (n = 7), generalized anxiety disorder (n = 2) and anorexia nervosa (n = 1).
Two groups were identified according to the frequency of participation: 'completers' (n = 42) and 'drop-out' (n = 58). The groups did not differ significantly in any socio-demographic variable or the TERS total score (see Table 2 ).
Relapses measured by EtG
During the course of eleven sessions we expected to collect a maximum of 1100 urinary samples from 100 participants. In the end 602 urinary samples were delivered, which is 78.9% of the 763 times patients had attended sessions. A total of 21.6% (n = 130) of the samples demonstrated positive EtG results, suggesting relapse. The number of delivered samples decreased continuously from 88 in the patient's first session to 14 in the last (Fig. 2) . The percentage of positive EtG results decreased from 27.3% in the first session to 7.1% in the last (Fig. 2) .
The completer group delivered urinary samples in 85.4% of their attended sessions, compared with only 70.8% in the drop-out group (P = 0.012, Fig. 3 ). From these delivered samples, 16.5% tested positive in the completer group in comparison to 30.5% in the drop-out group (P < 0.001). In detail, only 25 of the 42 completers never delivered a positive sample yielding a relapse rate of 40.5%. Adjusted for the rate of attendance, this means that a relapse was confirmed in 14.2% of the sessions attended by a completer. In the drop-out group 38 of the 58 patients had only delivered negative samples before, yielding a confirmed relapse rate of 34.5%. Adjusted for the rate of attendance, a relapse was confirmed in 24.0% of the attended sessions.
DISCUSSION
The present study is the first to our knowledge examining feasibility and acceptability of addiction therapy in ALD patients awaiting liver transplantation. Besides a high acceptance of the program our results show that for the whole patient group, a decrease in relapses Note: Sample sizes vary due to missing data (displayed in positive EtG results) occurred during the course of the treatment, as well as a decrease in delivered urinary samples. Comparing the groups of completers and drop-outs, a significant difference was revealed: patients who attended at least three quarters of the sessions had proportionally less relapses than patients who attended less than nine sessions. The decrease in the amount of relapses suggests that offering addiction therapy for ALD patients awaiting liver transplantation might be a helpful intervention in that patients who participated in nearly all of the sessions did best. Completers may have had a higher motivation to stay abstinent from the beginning, but attending the addiction therapy continuously might have helped in pursuing the goal. However, the other half of the participants were unable to complete the therapy sessions. These patients may have had more severe addiction problems and/or more severe physical problems. The therapy program we offered therefore does not seem appropriate for such patients. An inpatient rehabilitation setting could give more support to patients with advanced addiction/physical problems. Generally, in both the completer and drop-out groups, there were patients who felt the urge to consume alcohol and had relapses during the therapy. As the detection times for urinary EtG depend on the amount of ethanol intake it may be that there were more relapses than actually have been detected. The results are in accordance with Weinrieb et al. (2001) , who found that liver transplant patients struggle with abstinence in the pre-transplantation period. The frequency of alcohol consumption during the waiting time for transplantation is high and may be underestimated. We regard this to be crucial evidence of the necessity for supportive addiction therapies for liver transplant patients waiting for a transplant. Learning impulse control strategies, working out situational preconditions of a relapse and improving alternative coping mechanisms are important components supporting abstinence. The continuous measurement and feedback of alcohol consumption was an important intervention, perhaps motivating patients to work on behavioral and situational strategies to prevent relapse. Knowing that the setting of transplantation reduces the validity of alcohol self-report measures (Schieber et al., 2015) , we decided on a biomarker. We also offered the patients the possibility to report relapses voluntarily during the sessions but in our experience, few patients would have reported alcohol consumption without the biochemical evidence. Therefore, the results of these measurements allow an open discussion and analysis of the jeopardizing situations. Similar results were found in studies showing that a feedback device (electronically compiled medication dosing histories) is very effective in enhancing medication adherence (Demonceau et al., 2013) . Once relapses are detected, it remains a therapeutic challenge to motivate patients to work on behavioral changes. In our groups, instead of just confronting the addiction, we used motivational interviewing (Miller and Rollnick, 1991) aimed to help foster a change in ideas and focused on how to establish improved health behaviors, including staying abstinent.
Although liver transplantation for ALD patients has been a wellaccepted indication in the last decade, clinicians have few empirically tested interventions available to assist ALD patients with ongoing alcohol consumption. Our therapy concept demonstrates a rationale for much needed psychiatric and addiction treatment services for ALD patients prior to transplantation. The need of an addiction treatment in the setting of liver transplantation is supported also by an European research group that claim a model of good practice consisting of an addiction treatment before and at least one year after transplantation (Dom et al., 2015) .
However, future research is needed to determine reliable measures for detecting alcohol consumption, and to establish psychological interventions for patients with alcohol abuse who are waiting for liver transplantation, as well as special interventions for patients with severe addiction problems. From an ethical point of view transplant centers should support transplantation candidates in their efforts to refrain from alcohol, as addictive behavior is a mental disorder that requires specialized therapies.
Interpretation of results and conclusions must be tempered with consideration of study limitations. We have to acknowledge that a randomization would have been the gold standard to report the effectiveness of the group therapy. For ethical reasons we provided the therapy program to all patients that fulfilled the inclusion criteria. Thus, there was no control group without treatment, a serious limitation of the study. Moreover, for practical reasons we used the medical history reports to assess psychiatric comorbidities, although we have to admit that conducting a structured clinical interview would have been a more valid procedure. For the interpretation of the results it would have been important to assess reasons for non-attending the treatment sessions. Unfortunately, we do not have any data regarding this point. We followed the therapeutic concept to reinforce participation, whereas reasons for absence were not brought into focus. Future studies should necessarily gather this information.
The study followed a naturalistic design and was conducted with participants from a single center, so results may not be able to be generalized broadly. Furthermore, there is no post-transplant follow-up data about the patients available, which may have been of great interest. However, the high sample size, the use of a manualized therapy in a standardized format and the use of an objective measurement of relapses, enriched the quality of the study.
CONCLUSIONS
The present study shows that an addiction therapy is feasible and accepted by the patients. Our addiction therapy including disclosure of the urinary EtG results appears to support amelioration in ALD patients prior to liver transplantation. This indicates a relevant and uncovered need for psychiatric and addiction treatment services for this population. We suggest that alcohol consumption of ALD patients in the waiting time is widely underestimated in clinical practice. Further research is needed to improve addiction therapy programs, and we suggest including the use of a biomarker feedback.
